
Clinical development platforms typically evolve with technology advances and scientific breakthroughs. Notably, the COVID-19 pandemic accelerated the adoption of digital technologies, data science, analytics, and automation tools, enabling remote services and preserving the continuity of care.
A unified clinical development platform with improved data architecture and analytics capabilities can accelerate the drug development process and enrich the experience for sponsors, patients, and physicians. In recent years, the industry has pivoted from questioning the existence of end-to-end platforms to creating a near-term vision for adopting such platforms.
-
Clinical Development Platforms Products PEAK Matrix® Assessment 2022
What is in this PEAK Matrix® Report:
Everest Group’s Clinical Development Platforms Products PEAK Matrix® Assessment 2022 looks at the vendor landscape of clinical development platforms and presents in-depth analysis and insights on these platforms. We assess the capabilities of 22 clinical development platform vendors and map them on the Everest Group PEAK Matrix®, a composite index of distinct metrics related to a vendor’s capability and market impact.
Scope:
- Industry: life sciences
- Geography: global
READ ON
What is the PEAK Matrix®?
The PEAK Matrix® provides an objective, data-driven assessment of service and technology providers based on their overall capability and market impact across different global services markets, classifying them into three categories: Leaders, Major Contenders, and Aspirants.